Hangzhou DAC Biotech Co., Ltd focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drugs.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 12, 2021 | Series C | ¥1B | 2 | — | — | Detail |
Jan 12, 2018 | Series B | ¥20M | 1 | — | — | Detail |
May 26, 2017 | Series A | ¥50M | 1 | Huahai Yaoye | — | Detail |
Oct 22, 2013 | Seed | ¥1M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Huahai Yaoye | Yes | Series A |
Kwai Hung Group | — | Series C |
Tigeryeah Capital | — | Series C |
Jinyongxin Investment Management | — | Series B |
Jinji Yiyao Touzi | — | Seed |